CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer

The Institute of Cancer Research0 sites1,178 target enrollmentMarch 24, 2017

ConditionsProstate cancer Cancer Malignant neoplasm of prostate

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Prostate cancer
Sponsor: The Institute of Cancer Research
Enrollment: 1178
Status: Terminated
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 24, 2017

End Date

January 31, 2022

Last Updated

6 years ago

Study Type

Interventional

Sex

Male

Investigators

Sponsor

The Institute of Cancer Research

Eligibility Criteria

Inclusion Criteria

•1\. Written informed consent
•2\. Male patients over and including 18 years on the date of consent
•3\. Histologically confirmed diagnosis of adenocarcinoma of the prostate with availability of archival tumour tissue for molecular analyses (small cell prostate cancer is an exclusion); if no histological diagnosis has ever been acquired a fresh tumour biopsy confirming the presence of CRPC must be pursued
•4\. Metastatic castration\-resistant disease with only bone metastases, confirmed by bone scan (within 4 weeks) or CT/ whole body MRI (within 6 weeks), of starting this trial (Cycle 1 Day 1\). Patients with local recurrence, and bone metastases with an associated soft tissue component, will be allowed into the trial. Pelvic lymphadenopathy \<2cm in size is not an exclusion.
•5\. Systemic chemotherapy indicated for disease progression, defined as:
•5\.1\. Bone Scan Progression: Two or more documented new bone lesions over previous 6 months
•5\.2\. Increasing serum PSA level: Two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart are required. If the third PSA value is less than the second, an additional fourth test to confirm the rising PSA is required
•6\. Baseline laboratory values as stated below:
•6\.1\. Creatinine \=1\.5 x upper limit of normal (ULN)
•6\.2\. Bilirubin \=1\.0 x ULN

Exclusion Criteria

•1\. Received any prior cytotoxic chemotherapy as treatment for castration\-resistant prostate cancer. Patients that have received chemotherapy for hormone\-sensitive metastatic prostate cancer will be allowed onto the trial, if the patient merits retreatment with docetaxel and at least 12 months has elapsed since the patient has completed that previous docetaxel therapy.
•2\. Measurable soft tissue or lymph node metastases or any metastatic disease outside the bone that is RECIST measurable will be an exclusion (unless it is pelvic nodal disease \<2cm in size). Bone metastases with associated soft tissue components will also not be an exclusion.
•3\. Received any cycling, intermittent or continuous hormonal treatment 28 days prior to randomisation with the exception of the continuous LHRH analogues
•4\. History of or current documented brain metastasis or carcinomatous meningitis, treated or untreated. Brain imaging for asymptomatic patients is not required.
•5\. Current symptomatic cord compression requiring surgery or radiation therapy (once the patient is successfully treated the patient will be considered eligible for the study)
•6\. Active second malignancy (except non\-melanoma skin or superficial bladder cancer) defined as requiring anticancer therapy or within the previous two years
•7\. Serious medical conditions such as heart failure, myocardial infarction, pulmonary thromboembolism within 12 months; stroke or treatment of a major active infection within 3 months of randomisation, as well as any significant medical illness that in the opinion of the Investigator would preclude protocol therapy
•8\. Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device. Concomitant participation in observational studies is acceptable.
•9\. Hypersensitivity to the active substance, to any of its excipients (including polysorbate 80\) or to other taxanes
•10\. Concomitant vaccination with yellow fever vaccine